Dr. Roger L. Aamodt This is Me

Education

 Web References

1. 1. 2005 Annual Meeting - American Association for Cancer Research

   services.aacr.org/2005AM/sched - [Cached]

   Published on: 11/20/2004   Last Visited: 12/19/2004

   Chairperson: Roger L. Aamodt, National Cancer Institute, Rockville, MD

2. 2. Journal of Translational Medicine | Full text | From bench to clinic and back: Perspective on the 1stIQPC Translational Research conference

   www.translational-medicine.com - [Cached]

   Published on: 9/1/2004   Last Visited: 7/21/2006

   Roger L. Aamondt, PhD, Chief, Resources Development Branch, NCI.

3. 3. Brisk trade in tissue for proteomics and genomics research - College of American Pathologists

   www.cap.org/apps/docs/cap_toda - [Cached]

   Published on: 3/1/2003   Last Visited: 12/6/2004

   "We basically make tissue available to people who call and ask, and pharmaceutical and clinical diagnostics companies have access as long as they are doing research and not incorporating the tissues into product development," says Roger Aamodt, PhD, chief of the NCI's Resources Development Branch and president of the International Society for Biological and Environmental Repositories.
   
   While NCI is in close contact with the big pharmaceutical companies, it has no formal relationship with them. "We feel we're serving pretty much a different constituency," Dr. Aamodt says. But commercial and academic researchers can use NCI's specimen resource locator or "tissue expediter," which functions as a single point of contact for researchers looking for tissues. In many cases, researchers don't have any other means of learning about these tissues because they're not commercially available.
   
   A more elaborate effort underway at NCI is the Shared Pathology Informatics Network, or SPIN, which will use state-of-the-art informatics techniques to establish an Internet-based virtual database. "This will allow researchers to query a large number of institutions' electronic clinical information systems and pull out a listing of what pathology specimens are there that will meet their research needs," Dr. Aamodt says.
   ...
   "Law regarding ownership of specimens is very complicated and confusing at this point," Dr. Aamodt says. The California Supreme Court, in Moore v. Regents of the University of California, ruled in 1990 that a patient does not have a continuing ownership interest in his excised cells and tissue used in research. However, the court also held that the failure to inform a patient that his collected tissue would be used for research purposes was a breach of the duty to obtain informed consent.
   ...
   More rigorous rules will take effect April 14, Dr. Aamodt says. "The regulation of tissue banking is the same as rules applying to any other human subject research, and the Department of Health and Human Services is about to implement new rules under the Health Insurance Portability and Accountability Act. These rules will significantly strengthen privacy and confidentiality controls,probably with some major negative impact on research," he says.
   
   Most tissue research is considered to pose "minimal risk" to patients, but the new privacy rules have extensive administrative requirements that apply whether or not there is a determination of increased risk. If it is health data and is identifiable, then it requires additional administrative procedures.
   
   "Because the rules are very complicated, it will take the research community some time to fully understand what they mean and how they apply," Dr. Aamodt says.